The cardiorenal syndrome: A mutual approach to concomitant cardiac and renal failure

Israel Medical Association Journal

Volumn 14, Issue 9, 2012, Pages 570-576

  Ben Shoshan, Jeremy ^a,b   Entin Meer, Michal ^a,b   Guzner Gur, Hanan ^a,b   Keren, Gad ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cardiorenal syndrome (CRS); Creatinine; Heart failure (HF); Myocardial dysfunction; Renal failure (RF)

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CARVEDILOL; CYSTATIN C; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; HYDRALAZINE; METOPROLOL; MILRINONE; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITRATE; NORADRENALIN; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ACUTE GLOMERULONEPHRITIS; ANEMIA; CARDIOGENIC SHOCK; CARDIORENAL SYNDROME; CATHETER ABLATION; CONCURRENT INFECTION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISSEMINATED INTRAVASCULAR CLOTTING; ELECTROLYTE DISTURBANCE; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; HYPERLIPIDEMIA; HYPOVOLEMIA; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY ISCHEMIA; MORBIDITY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; REVIEW; SEPSIS; SIDE EFFECT; DISEASE COURSE; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; RISK FACTOR;

CARDIO-RENAL SYNDROME; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HEMODYNAMICS; HUMANS; RISK FACTORS;

EID: 84871911410     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149 (2): 209-16.
2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339 (12): 799-805.
3. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47 (3): 884-90.
4. Wali RK, Wang GS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005; 45 (7): 1051-60.
5. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34 (5): 957-62.
6. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43 (1): 61-7.
7. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341 (8): 577-85.
8. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53 (7): 589-96.
9. Burnett JC, Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol 1980; 238 (4): F279-82.
10. Zoccali C, Mallamaci F, Benedetto FA, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12 (7): 1508-15.
11. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1- receptor antagonist, in acute heart failure. N Engl J Med 2010; 363 (15): 1419-28.
12. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol 2003; 14 (6): 1549-58.
13. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2001; 57 (4): 846-51.
14. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of- principle cohort study. Lancet 2009; 373 (9671): 1275-81.
15. Silverberg DS, Wexler D, Blum M, et al. The interaction between heart failure, renal failure and anemia - the cardio-renal anemia syndrome. Blood Purif 2004; 22 (3): 277-84.
16. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92 (5): 625-8.
17. Schwartzenberg S, Ben-Shoshan J, Keren G, George J. The role of erythropoietin in myocardial protection: potential mechanisms and applications. Exp Rev Cardiovasc Ther 2006; 4 (1): 41-50.
18. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362 (9): 779-89.
19. Drexler H, Höing S, Faude F, Just H, et al. Central and regional vascular hemodynamics following intravenous milrinone in the conscious rat: comparison with dobutamine. J Cardiovasc Pharm 1987; 9 (5): 563-9.
20. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96 (9 Suppl): II-286-90.
21. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362 (9377): 7-13.
22. Jentzer JC, DeWald TA, Hernandez AF, et al. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56 (19): 1527-34.
23. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341 (10): 709-17.
24. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the International Society for Heart and Lung Transplantation endorsed by the Heart Failure Society of America. J Am Coll Cardiol 2011; 38 (7): 2101-13.
25. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362 (9386): 772-6.
26. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314 (24): 1547-52.
27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336 (8): 525-33.
28. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70 (4): 479-87.
29. Authors/Task Force members, et al. Focused Update of ESC Guidelines on device therapy in heart failure. Europace 2010; 12 (11): 1526.
30. Das M. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death. Expert Rev Cardiovasc Ther 2009; 7 (2): 181-95.
31. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchro- nization on morbidity and mortality in heart failure. N Engl J Med 2005; 352 (15): 1539-49.
32. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin- converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42 (2): 201-8.
33. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast agent- induced nephropathy by hemofiltration. N Engl J Med 2003; 349 (14): 1333-40.
34. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25 (12): 1021-8.
35. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35 (7): 1737-44.
36. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355 (20): 2085-98.
37. Locatelli F, Aljama P, Canaud B, et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25 (9): 2846-50.
38. Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007; 35 (10): 2408-16.
39. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345 (19): 1368-77.
40. Singer P, Cohen JD. The Surviving Sepsis Campaign guidelines: should we follow? IMAJ Isr Med Assoc J 2011; 13 (11): 692-3.